Rep. Virginia Foxx Sells Bristol Myers Squibb Company (NYSE:BMY) Shares

Representative Virginia Foxx (R-North Carolina) recently sold shares of Bristol Myers Squibb Company NYSE: BMY. In a filing disclosed on July 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol Myers Squibb stock on June 24th.

Representative Virginia Foxx also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Ellington Financial NYSE: EFC on 6/30/2025.
• Sold $15,001 - $50,000 in shares of Energy Transfer NYSE: ET on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of Hercules Capital NYSE: HTGC on 5/20/2025.
• Purchased $1,001 - $15,000 in shares of Alliance Resource Partners NASDAQ: ARLP on 5/15/2025.

Bristol Myers Squibb Stock Up 1.9%

Shares of Bristol Myers Squibb stock traded up $0.90 during trading on Thursday, reaching $48.07. The company had a trading volume of 16,469,747 shares, compared to its average volume of 12,799,975. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb Company has a fifty-two week low of $41.61 and a fifty-two week high of $63.33. The firm's fifty day moving average is $47.45 and its 200-day moving average is $53.00. The company has a market cap of $97.82 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.43 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period last year, the business posted ($4.40) earnings per share. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.16%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Institutional Trading of Bristol Myers Squibb

Several hedge funds have recently modified their holdings of BMY. LaFleur & Godfrey LLC raised its position in Bristol Myers Squibb by 3.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 1,487 shares during the last quarter. Brighton Jones LLC raised its position in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new position in Bristol Myers Squibb in the 4th quarter worth approximately $13,094,000. Schechter Investment Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter worth approximately $536,000. Finally, Steward Partners Investment Advisory LLC raised its position in Bristol Myers Squibb by 5.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 156,751 shares of the biopharmaceutical company's stock worth $8,866,000 after purchasing an additional 7,624 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BMY. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler assumed coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Finally, Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $57.69.

About Representative Foxx

Virginia Foxx (Republican Party) is a member of the U.S. House, representing North Carolina's 5th Congressional District. She assumed office on January 3, 2005. Her current term ends on January 3, 2027. Foxx (Republican Party) ran for re-election to the U.S. House to represent North Carolina's 5th Congressional District. She won in the general election on November 5, 2024. Foxx was born in New York, New York. She earned a B.A. and M.A.C.T. from the University of North Carolina, Chapel Hill, in 1968 and 1972, respectively, and an Ed.D. from the University of North Carolina, Greensboro, in 1985. Foxx worked as an instructor at Caldwell Community College in Hudson, NC, and an instructor and assistant dean at Appalachian State University in Boone, NC. She owned a landscape nursery and served as Deputy Secretary for Management at the North Carolina Department of Administration.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.